Acura NanoMedicine Corporation
Update：2025/10/08
Industries
Main Industry
Health Care
Main Product/Service
1. Out-licensing of innovative drug products, including the AN-8 series, a novel therapy designed to reverse cancer drug resistance, and other pharmaceuticals.
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2) three nanomedicine delivery platforms to engage in joint new drug development and licensing partnerships
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2) three nanomedicine delivery platforms to engage in joint new drug development and licensing partnerships
Founded Year
2017
Unified Business No.
52805302
Status
Active
Number of Employees
4
Total Paid-in
Capital
25,014,700 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Acura NanoMedicine is one of the few dual-platform technology new drug companies in the world. We integrate AI big data drug discovery platform and nano drug delivery system platform to develop a series of nano anticancer drugs (AN-8 series & others) that are highly effective to overcome a variety of difficult-to-treat cancers such as drug-resistant pancreatic cancer/brain cancer, etc. At the same time, we also use our platform technologies to cooperate with other new drug companies to form a joint development network for co-development new drugs.
